TLRY - Tilray, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Leamington,
Canada
Type: Equity
TLRY price evolution
TLRY
| (in millions $) | 30 Oct 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $146.25 | $144.95 | $179.13 | |
| Short term investments | $79.61 | $116.42 | $287.33 | |
| Net receivables | $89.54 | $90.6 | $82.08 | |
| Inventory | $244.14 | $252.7 | $232.07 | |
| Total current assets | $631.21 | $642.03 | $829.25 | |
| Long term investments | $40.06 | $87.35 | $86.88 | |
| Property, plant & equipment | $596.24 | $628.64 | $500.22 | |
| Goodwill & intangible assets | $2939.74 | $2963.13 | $2977.24 | |
| Total noncurrent assets | $3581.64 | $3688.53 | $3572.99 | |
| Total investments | $119.66 | $203.77 | $374.22 | |
| Total assets | $4212.86 | $4330.56 | $4402.25 | |
| Current liabilities | ||||
| Accounts payable | $209.76 | $216.9 | $238.08 | |
| Deferred revenue | ||||
| Short long term debt | $116.16 | $166.62 | $282 | |
| Total current liabilities | $329.1 | $394.99 | $537.27 | |
| Long term debt | $365.46 | $362.76 | $280.71 | |
| Total noncurrent liabilities | $540.72 | $542.22 | $463.42 | |
| Total debt | $481.62 | $529.38 | $562.71 | |
| Total liabilities | $869.82 | $937.2 | $1000.69 | |
| Shareholders' equity | ||||
| Retained earnings | -$2628.74 | -$2536.04 | -$2487.03 | |
| Other shareholder equity | -$43.19 | -$38.37 | -$43.56 | |
| Total shareholder equity | $3358.86 | $3368.34 | $3379.37 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $206.63 | $415.91 | $488.47 | $189.7 |
| Short term investments | $241.9 | $2.48 | $15.98 | |
| Net receivables | $86.23 | $95.28 | $87.31 | $29.03 |
| Inventory | $200.55 | $245.53 | $256.43 | $93.64 |
| Total current assets | $773.03 | $803.5 | $883.61 | $347.02 |
| Long term investments | $115.77 | $126.2 | $17.68 | $23.67 |
| Property, plant & equipment | $435.61 | $600.5 | $668.97 | $217.54 |
| Goodwill & intangible assets | $2982.63 | $3919.18 | $4438.71 | $353.36 |
| Total noncurrent assets | $3534.23 | $4646.19 | $5141.75 | $598.93 |
| Total investments | $357.67 | $126.2 | $20.17 | $23.67 |
| Total assets | $4307.26 | $5449.69 | $6025.36 | $945.95 |
| Current liabilities | ||||
| Accounts payable | $190.68 | $157.43 | $212.81 | $17.78 |
| Deferred revenue | ||||
| Short long term debt | $224.26 | $92.65 | $49.6 | |
| Total current liabilities | $432.98 | $280.34 | $401.24 | $181.28 |
| Long term debt | $365.87 | $531.16 | $889.06 | $306.26 |
| Total noncurrent liabilities | $544.34 | $727.99 | $1158.81 | $390.77 |
| Total debt | $590.13 | $623.81 | $938.66 | $306.26 |
| Total liabilities | $977.32 | $1008.33 | $1560.05 | $572.05 |
| Shareholders' equity | ||||
| Retained earnings | -$2415.51 | -$962.85 | -$486.05 | -$730.1 |
| Other shareholder equity | -$46.61 | -$20.76 | $152.67 | $8.21 |
| Total shareholder equity | $3315.69 | $4398.81 | $4459.07 | $373.9 |
| (in millions $) | 30 Oct 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $188.34 | $176.95 | ||
| Cost of revenue | $138.94 | $132.75 | ||
| Gross Profit | $49.4 | $44.2 | ||
| Operating activities | ||||
| Research & development | $0.11 | $0.08 | ||
| Selling, general & administrative | $61.13 | $55.91 | ||
| Total operating expenses | $137.48 | $89.67 | ||
| Operating income | -$88.08 | -$45.47 | ||
| Income from continuing operations | ||||
| EBIT | -$87.06 | -$54.43 | ||
| Income tax expense | -$2.87 | $7.26 | ||
| Interest expense | $8.52 | $9.84 | ||
| Net income | ||||
| Net income | -$92.7 | -$71.53 | ||
| Income (for common shares) | -$92.7 | -$71.53 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $627.12 | $628.37 | $513.09 | $210.48 |
| Cost of revenue | $480.16 | $511.56 | $389.9 | $185.83 |
| Gross Profit | $146.96 | $116.82 | $123.18 | $24.66 |
| Operating activities | ||||
| Research & development | $0.68 | $1.52 | $0.83 | $4.41 |
| Selling, general & administrative | $230.94 | $228.66 | $155.69 | $140.55 |
| Total operating expenses | $1515.79 | $771.87 | $255.35 | $219.8 |
| Operating income | -$1368.83 | -$655.05 | -$132.17 | -$195.14 |
| Income from continuing operations | ||||
| EBIT | -$1446.25 | -$455.4 | -$348.42 | -$237.46 |
| Income tax expense | -$7.18 | -$6.54 | -$8.97 | -$5.6 |
| Interest expense | $13.59 | $27.94 | $27.98 | $39.22 |
| Net income | ||||
| Net income | -$1452.66 | -$476.8 | -$367.42 | -$271.07 |
| Income (for common shares) | -$1452.66 | -$476.8 | -$367.42 | -$271.07 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | -$92.7 | -$49.01 | -$71.53 | -$138.71 |
| Operating activities | ||||
| Depreciation | $32.84 | $31.55 | $30.79 | $28.99 |
| Business acquisitions & disposals | -$83.58 | $22.96 | $1.4 | |
| Stock-based compensation | $8.06 | $8.2 | $8.26 | $9.83 |
| Total cash flows from operations | -$15.36 | -$30.41 | -$15.84 | $43.6 |
| Investing activities | ||||
| Capital expenditures | -$8.73 | -$5.84 | -$3.81 | -$10.28 |
| Investments | $36.81 | $45.44 | -$45.44 | $1.29 |
| Total cash flows from investing | $28.09 | $81.5 | -$26.29 | -$7.58 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$10.91 | -$85.37 | $14.02 | $6.24 |
| Total cash flows from financing | -$10.91 | -$85.37 | $14.02 | $6.24 |
| Effect of exchange rate | -$0.51 | $0.1 | $0.61 | -$0.61 |
| Change in cash and equivalents | $1.3 | -$34.18 | -$27.5 | $41.63 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$1452.66 | -$476.8 | -$367.42 | -$271.07 |
| Operating activities | ||||
| Depreciation | $130.15 | $154.59 | $67.83 | $18.65 |
| Business acquisitions & disposals | -$26.72 | $0.33 | $75.04 | |
| Stock-based compensation | $39.59 | $35.99 | $17.35 | $29.72 |
| Total cash flows from operations | $7.91 | -$177.26 | -$44.72 | -$129.35 |
| Investing activities | ||||
| Capital expenditures | -$16.5 | -$21.86 | -$32.27 | -$41.98 |
| Investments | -$241.9 | $3.33 | $0.3 | |
| Total cash flows from investing | -$285.11 | -$21.53 | $46.1 | -$41.68 |
| Financing activities | ||||
| Dividends paid | -$23.89 | |||
| Sale and purchase of stock | $128.4 | $259.23 | $102.69 | $220.2 |
| Net borrowings | -$58.25 | -$123.55 | $45.51 | $43.29 |
| Total cash flows from financing | $70.16 | $128.2 | $124.31 | $264.85 |
| Effect of exchange rate | -$2.23 | -$1.96 | $2.12 | -$0.91 |
| Change in cash and equivalents | -$209.28 | -$72.56 | $127.82 | $92.91 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.29 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |